Reference number : GC-2017-Q2-00048, amendment number : , agreement type : G, recipient legal name : Levin, David (University of Manitoba)|Levin, David (Université du Manitoba), recipient country : CA, recipient province : nan, recipient city : Manitoba, recipient postal code : nan, program name english : Engage Grants for Universities, program name french : Subventions d'engagement partenarial pour les universités, program purpose english : Kane Biotech Inc. is a Manitoba-based company that provides innovative technologies that break down and_x000D_
disperse microbial biofilms. Its mission is to discover and commercialize new technologies that will prevent_x000D_
biofilm-related infections in human and animal healthcare, as well as biofilm-related industrial applications._x000D_
Dispersin B has been shown to both inhibit and disperse bacterial biofilms. Kane Biotech Inc. has expressed_x000D_
this enzyme protein in E. coli, with the goal of developing Dispersin B-based products. Dispersin B yield and_x000D_
the cost effective commercial production of the enzyme are critical factors affecting the market opportunities_x000D_
for Kane Biotech's Dispersin B products, estimated to be $10 million in the next few years. Kane Biotech will_x000D_
partner with Dr. David Levin, in the Department of Biosystems Engineering at the University of Manitoba, in a_x000D_
joint research project to optimize production of Dispersin B. The specific goals of the proposed research are to_x000D_
identify an animal-product-free (APF) cell culture medium that supports maximal cell mass production and_x000D_
Dispersin B yields, and develop a scale-up fermentation process using the best APF medium in a bioreactor_x000D_
system., program purpose french : Kane Biotech Inc. is a Manitoba-based company that provides innovative technologies that break down and_x000D_
disperse microbial biofilms. Its mission is to discover and commercialize new technologies that will prevent_x000D_
biofilm-related infections in human and animal healthcare, as well as biofilm-related industrial applications._x000D_
Dispersin B has been shown to both inhibit and disperse bacterial biofilms. Kane Biotech Inc. has expressed_x000D_
this enzyme protein in E. coli, with the goal of developing Dispersin B-based products. Dispersin B yield and_x000D_
the cost effective commercial production of the enzyme are critical factors affecting the market opportunities_x000D_
for Kane Biotech's Dispersin B products, estimated to be $10 million in the next few years. Kane Biotech will_x000D_
partner with Dr. David Levin, in the Department of Biosystems Engineering at the University of Manitoba, in a_x000D_
joint research project to optimize production of Dispersin B. The specific goals of the proposed research are to_x000D_
identify an animal-product-free (APF) cell culture medium that supports maximal cell mass production and_x000D_
Dispersin B yields, and develop a scale-up fermentation process using the best APF medium in a bioreactor_x000D_
system., agreement title english : Optimization of Dispersin B production in Escherichia coli., agreement title french : Optimization of Dispersin B production in Escherichia coli., agreement number : EGP, agreement value : 25000.0, agreement start date : 2017-07-12, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year (2017-2018 to 2018-2019)., additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2018-2019)., owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada